Abstract 1278P
Background
The first interim analysis of the phase 3 INSPIRE study (NCT04632758) (data cutoff: Nov 13, 2022) showed that iruplinalkib significantly improved PFS versus crizotinib in patients (pts) with advanced ALK+ and ALK TKI-naïve NSCLC. Here we present updated survival and safety results after additional follow-up.
Methods
Pts with ALK+, stage IIIB/IV NSCLC naïve to ALK TKI were randomized (1:1) to oral iruplinalkib 180 mg QD (7-day run-in at 60 mg QD) or crizotinib 250 mg BID. The primary endpoint was PFS assessed by Independent Review Committee (IRC) per the RECIST version 1.1. Secondary endpoints included PFS by investigator (INV), OS and safety.
Results
From Sep 4, 2019 to Dec 2, 2020, 292 pts were randomized (iruplinalkib/crizotinib, n=143/149). The data cutoff date of this updated analysis was Oct 25, 2023. Median follow-up for PFS by IRC was 35.02 months for iruplinalkib and 34.96 months for crizotinib. Median PFS by IRC was 36.80 months for iruplinalkib and 14.55 months for crizotinib (HR, 0.311 [98.02% CI, 0.222-0.436]; stratified one-sided log-rank p<0.0001). Other efficacy results are presented in the table. Incidence of ≥ grade 3 treatment-related AEs was 53.1% for iruplinalkib and 51.0% for crizotinib.
Conclusions
These results demonstrated iruplinalkib continued to improve PFS versus crizotinib in pts with advanced ALK+ and ALK TKI-naïve NSCLC. The safety profile was consistent with prior results and no new safety findings was observed. Table: 1278P
Updated survival results of iruplinalkib versus crizotinib
| Iruplinalkib (n=143) | Crizotinib (n=149) | |
| mPFS by INV, mo (95% CI) | 31.11 (23.98-38.60) | 14.75 (11.10-16.56) |
| HR (95% CI) | 0.423 (0.312-0.573) | |
| mPFS in ALK+ pts by IRC, mo (95% CI) | 45.90 (28.32-NE) | 14.55 (11.07-16.53) |
| HR (95% CI) | 0.292 (0.199-0.430) | |
| mPFS in pts with baseline CNS metastases by IRC, mo (95% CI) | 26.25 (18.27-NE) | 11.01 (7.46-14.72) |
| HR (95% CI) | 0.215 (0.103-0.449) | |
| mPFS in pts without baseline CNS metastases by IRC, mo (95% CI) | 45.90 (29.50-NE) | 16.39 (12.88-18.30) |
| HR (95% CI) | 0.330 (0.222-0.489) | |
| 36-mo OS rate (%) (95% CI) | 81.3 (73.8-86.9) | 75.8 (67.8-82.1) |
Note: ALK+ pts were those whose ALK status was confirmed positive by both central laboratory and local hospitals.
Clinical trial identification
NCT04632758.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
M. Si, H. Li, L. Li, X. Kang: Other, Personal, Full or part-time Employment: Qilu Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1270P - Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial
Presenter: Sehhoon Park
Session: Poster session 05
1271P - Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC
Presenter: Hakan Bozcuk
Session: Poster session 05
1272P - Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Presenter: Jin-Ji Yang
Session: Poster session 05
Resources:
Abstract
1274P - Osimertinib versus first/second generation tyrosine kinase inhibitors as first-line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: Overall survival using real-world data from TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 05
1276P - EXcellenT (exercise in extended oncogene addicted lung cancer in active treatment) trial: Preliminary results on impact of physical activity (PA) on emotional, metabolic and immune status
Presenter: Chiara Bennati
Session: Poster session 05
1277P - Optimising targeted therapy in NSCLC: A comprehensive analysis of oncogenic fusion mutations and co-mutation landscapes
Presenter: Li Dongge
Session: Poster session 05
1279P - First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
Presenter: Yi-Long Wu
Session: Poster session 05
1280P - Effects of semaglutide on the exposure of alectinib in patients with NSCLC
Presenter: Daan Lanser
Session: Poster session 05
1281P - Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib
Presenter: Niels Heersche
Session: Poster session 05